Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations.

Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models ...

Late-stage results Otsuka presented in IgA nephropathy triggered a sell-off in Vera shares. Elsewhere, investors scrutinized ...

Results from the Phase III VERITAC-2 trial demonstrated that vepdegestrant reduced the risk of disease progression or death ...

June 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with its partner ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Job cuts at home-grown pharma companies like Arvinas and RallyBio and federal policies challenge CT biotech 'ecosystem' that ...

Arvinas noted that vepdegestrant, which is being developed alongside Pfizer to treat certain types of advanced or metastatic breast cancer, was generally well tolerated in the clinical trial, and that ...

Fintel reports that on June 2, 2025, Leerink Partners downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Outperform to ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

H.C. Wainwright analyst Andrew Fein notes that Arvinas (ARVN) shared the final data from the VERITAC-2 trial, which the firm sees positioning ...

June 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with its partner Pfizer ...